Expression of the RIP-1 gene and its role in growth and invasion of human gallbladder carcinoma

Cellular Physiology and Biochemistry

Volumn 34, Issue 4, 2014, Pages 1152-1162

  Zhu, Guangwei ^a   Chen, Xiao ^a   Wang, Xiaoqian ^a   Li, Xiujin ^a   Du, Qiang ^a   Hong, Haijie ^a   Tang, Nanhong ^a   She, Feifei ^a   Chen, Yanling ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Gallbladder cancer; Invasion; Receptor interacting protein 1; siRNA, growth; Xenograft tumor

Indexed keywords

PLASMID VECTOR; SMALL INTERFERING RNA; AGFG1 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEOPORIN; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN C;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; FEMALE; GALLBLADDER CANCER CELL LINE; GALLBLADDER CARCINOMA; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; RECEPTOR INTERACTING PROTEIN 1 GENE; TUMOR GENE; TUMOR INVASION; TUMOR XENOGRAFT; CARCINOMA; CELL PROLIFERATION; GALLBLADDER TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84908609390     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000366328     Document Type: Article

References (40)

1. Donohue JH, Stewart AK, Menck HR: The National Cancer Data Base report on carcinoma of the gallbladder, 1989-1995. Cancer 1998;83:2618-2628.
2. Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH: Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 1996;224:639-646.
3. Cubertafond P, Gainant A, Cucchiaro G: Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg 1994;219:275-280.
4. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
5. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, La Vecchia C: Epidemiology of biliary tract cancers: an update. Ann Oncol 2009;20:146-159.
6. Wernberg JA, Lucarelli DD: Gallbladder cancer. Surg Clin North Am 2014;94:343-360.
7. Albores-Saavedra J, Alcantra-Vazquez A, Cruz-Ortiz H, Herrera-Goepfert R: The precursor lesions of invasive gallbladder carcinoma. Hyperplasia, atypical hyperplasia and carcinoma in situ. Cancer 1980;45:919-927.
8. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008;454:436-444.
9. Bryant T: Remarks on Some Cases of Inflammation of the Breast Simulating Cancer. Br Med J 1868;2:608-609.
10. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860-867.
11. Stanger BZ, Leder P, Lee TH, Kim E, Seed B: RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995;81:513-523.
12. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV: TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996;4:387-396.
13. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P: The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998;8:297-303.
14. Hur GM, Lewis J, Yang Q, Lin Y, Nakano H, Nedospasov S, Liu ZG: The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation. Genes Dev 2003;17:873-882.
15. Devin A, Lin Y, Liu ZG: The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep 2003;4:623-627.
16. Liu ZG, Hsu H, Goeddel DV, Karin M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996;87:565-576.
17. Bradley JR, Pober JS: Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001;20:6482-6491.
18. Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310.
19. Pacifico F, Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol 2006;72:1142-1152.
20. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr.: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-417.
21. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296.
22. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-759.
23. Zhu G, Du Q, Wang X, Tang N, She F, Chen Y: TNF-alpha promotes gallbladder cancer cell growth and invasion through autocrine mechanisms. Int J Mol Med 2014;33:1431-1440.
24. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, Zhao D, Bachoo RM, Pieper RO, Habib AA: The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res 2009;69:2809-2816.
25. Han W, Xie J, Fang Y, Wang Z, Pan H: Nec-1 Enhances Shikonin-Induced Apoptosis in Leukemia Cells by Inhibition of RIP-1 and ERK1/2. Int J Mol Sci 2012;13:7212-7225.
26. Azijli K, Yuvaraj S, Peppelenbosch MP, Wurdinger T, Dekker H, Joore J, van Dijk E, Quax WJ, Peters GJ, de Jong S, Kruyt FA: Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci 2012;125:4651-4661.
27. Homma S, Hasumura S, Nagamori S, Kameda H: [Establishment and characterization of a human gall bladder carcinoma cell line NOZ]. Hum Cell 1988;1:95-97.
28. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P: RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007;14:400-410.
29. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Jaattela M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nunez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B, Kroemer G: Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009;16:1093-1107.
30. Lee TH, Shank J, Cusson N, Kelliher MA: The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem 2004;279:33185-33191.
31. Miquel JF, Covarrubias C, Villaroel L, Mingrone G, Greco AV, Puglielli L, Carvallo P, Marshall G, Del Pino G, Nervi F: Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology 1998;115:937-946.
32. Andia ME, Hsing AW, Andreotti G, Ferreccio C: Geographic variation of gallbladder cancer mortality and risk factors in Chile: a population-based ecologic study. Int J Cancer 2008;123:1411-1416.
33. Diehl AK: Gallstone size and the risk of gallbladder cancer. JAMA 1983;250:2323-2326.
34. Chen Y, Jiang L, She F, Tang N, Wang X, Li X, Han S, Zhu J: Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Mol Cell Biochem 2010;345:77-89.
35. Lin W, Jiang L, Chen Y, She F, Han S, Zhu J, Zhou L, Tang N, Wang X, Li X: Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer. Cancer Lett 2012;314:127-136.
36. Bantounas I, Phylactou LA, Uney JB: RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 2004;33:545-557.
37. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
38. Cha HS, Bae EK, Koh JH, Chai JY, Jeon CH, Ahn KS, Kim J, Koh EM: Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J Rheumatol 2007;34:16-19.
39. Horiuchi H, Kawamata H, Fujimori T, Kuroda Y: A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 2003;23:957-963.
40. Du Q, Jiang L, Wang XQ, Pan W, She FF, Chen YL: Establishment of and Comparison between Orthotopic Xenograft and Subcutaneous Xenograft Models of Gallbladder Carcinoma. Asian Pac J Cancer Prev 2014;15:3747-3752.